Pharmaids Pharmaceuticals Limited

PHARMAID

INE117D01018

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 01:11:25 2024-06-26 EDT			5-day change	1st Jan Change
52 ^INR	+1.38%		+1.01%	+6.82%

05-28	Pharmaids Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI
05-28	Pharmaids Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI

Pharmaids Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2021

July 23, 2021 at 06:52 am

Pharmaids Pharmaceuticals Limited announced earnings results for the first quarter ended June 30, 2021. For the first quarter, the company announced total revenue was INR 23.416 million compared to INR 0.263 million a year ago. Net income was INR 0.101 million compared to INR 0.034 million a year ago. Basic earnings per share from continuing operations was INR 0.01.

Latest news about Pharmaids Pharmaceuticals Limited

Pharmaids Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-28	CI
Pharmaids Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-28	CI
Pharmaids Pharma Completes Acquisition of Adita Bio Sys	03-04	MT
Pharmaids Pharmaceuticals Limited completed the acquisition of 99.86% stake in Adita Bio Sys Private Ltd.	03-01	CI
Pharmaids Pharmaceuticals Limited announced that it has received INR 525.448343 million in funding from Asian Hotels Limited, Tumkur Trade Center Private Limited and another investors	03-01	CI
Pharmaids Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-12	CI
Pharmaids Pharmaceuticals Names Chairman; Shares Slip 5%	02-12	MT
Pharmaids Pharmaceuticals Buys Additional 1.25% Stake in Anugraha Chemicals	02-09	MT
Pharmaids Pharmaceuticals Limited Appoints Shankarappa Nagaraja Vinaya Babu as Non-Executive Non-Independent Director and Chairman	01-31	CI
Pharmaids Pharmaceuticals Limited agreed to acquire 99.86% stake in Adita Bio Sys Private Ltd. for INR 530 million.	01-06	CI
Pharmaids Pharmaceuticals Limited Approves the Appointment of Dr. Prasad S as Chief Executive Officer	01-06	CI
Pharmaids Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-11	CI
Pharmaids Pharmaceuticals Limited Announces Board Changes	23-08-29	CI
Pharmaids Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-04	CI
Pharmaids Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-29	CI
Pharmaids Pharmaceuticals Limited Announces Change in Registered Office Address	23-05-23	CI
Pharmaids Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-13	CI
Pharmaids Pharmaceuticals to Acquire Majority Stake in Anugraha Chemicals	23-01-25	MT
Pharmaids Pharmaceuticals Limited Announces Vyasmurti Madhavrao Shingatgeri Resigned from the Post of Independent Director of the Company	23-01-23	CI
Pharmaids Pharmaceuticals Approves Appointment of Pattamadai Natarajasarma Vijay as an Independent Director	23-01-03	CI
Pharmaids Pharmaceuticals to Raise $2 Million via Equity Offering; Shares Jump 7%	22-11-29	MT
Pharmaids Pharmaceuticals Limited Approves Resignation of Veerareddy Vallapureddy as Independent Director	22-11-29	CI
Pharmaids Pharmaceuticals Limited announced that it expects to receive INR 168 million in funding	22-11-28	CI
Pharmaids Pharmaceuticals Swings to Loss in Fiscal Q2	22-11-23	MT
Pharmaids Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-09	CI

Chart Pharmaids Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Pharmaids Pharmaceuticals Limited is an India-based suppliers of a range of specialty chemicals, skin care, hospital care and generic products in the areas of orthopedic, neuro and gastro, and other. The Company is engaged in the business of trading and manufacturing of generics, bulk drugs, and intermediaries, and other. The Company operates through Bulk Drugs and Intermediates segment. Its specialty chemicals products include Retinol, DL Alpha Tocopherol, D Pantothenate, Cyanocobalamin, Pyridoxine Hcl, Thiamine, Nicotinic Acid, Water Sol. Vitamin E, Coenzyme Q10 and D-Biotin. Its skin care products include Best care hands, Hands Sanitizer, Moisturizing Cream, Skinsure Plus, SkinSure Ultra, Alcohol Gel and Barrier Cream. Its hospital care products include Xepi Rub M, Facein Spray, Sod Hypochlorite, Sanmedin, Strumen G, Strumen TRIACID, Facein Eco, Facein Power 256, Facein Spray, Sod Hypochlorite, Wipes and PPE. Its generic products include Linzomust, Benfoshine, Duojoint, and other.

Sector

Pharmaceuticals

Calendar

2024-08-13 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PHARMAIDS PHARMACEUTICALS LIMITED	+6.82%	21.68M
ELI LILLY AND COMPANY	+55.19%	815B
NOVO NORDISK A/S	+47.26%	654B
JOHNSON & JOHNSON	-6.09%	354B
MERCK & CO., INC.	+21.92%	337B
ASTRAZENECA PLC	+18.40%	247B
ROCHE HOLDING AG	+3.64%	229B
NOVARTIS AG	+12.98%	219B
AMGEN INC.	+10.86%	171B
PFIZER, INC.	-2.78%	159B